"Deferoxamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
| Descriptor ID |
D003676
|
| MeSH Number(s) |
D02.092.570.394.265 D02.241.511.372.265
|
| Concept/Terms |
Deferoxamine- Deferoxamine
- Desferrioxamine
- Desferioximine
- Deferoxamine B
- Desferrioxamine B
- Deferoximine
- Deferrioxamine B
- Desferroxamine
Desferrioxamine B Mesylate- Desferrioxamine B Mesylate
- Mesylate, Desferrioxamine B
- Deferoxamine Mesilate
- Mesilate, Deferoxamine
- Deferoxamine Mesylate
- Mesylate, Deferoxamine
- Deferoxamine Methanesulfonate
- Methanesulfonate, Deferoxamine
|
Below are MeSH descriptors whose meaning is more general than "Deferoxamine".
Below are MeSH descriptors whose meaning is more specific than "Deferoxamine".
This graph shows the total number of publications written about "Deferoxamine" by people in this website by year, and whether "Deferoxamine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 1 | 2 |
| 2012 | 1 | 0 | 1 |
| 2015 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Deferoxamine" by people in Profiles.
-
Pervasive Genomic Damage in Experimental Intracerebral Hemorrhage: Therapeutic Potential of a Mechanistic-Based Carbon Nanoparticle. ACS Nano. 2020 03 24; 14(3):2827-2846.
-
Radiolabeling and Imaging of Adoptively Transferred Immune Cells by Positron Emission Tomography. Methods Mol Biol. 2020; 2097:267-272.
-
Treatment With Topical Deferoxamine Improves Cutaneous Vascularity and Tissue Pliability in an Irradiated Animal Model of Tissue Expander-Based Breast Reconstruction. Ann Plast Surg. 2019 01; 82(1):104-109.
-
The Italian multiregional thalassemia registry: Centers characteristics, services, and patients' population. Hematology. 2016 Aug; 21(7):415-24.
-
The Impact of Deferoxamine on Vascularity and Soft-Tissue Biomechanics in a Rat TRAM Flap Model. Plast Reconstr Surg. 2015 Jul; 136(1):125e-127e.
-
Deferoxamine mitigates radiation-induced tissue injury in a rat irradiated TRAM flap model. Plast Reconstr Surg. 2015 Jan; 135(1):124e-134e.
-
Deferoxamine reverses radiation induced hypovascularity during bone regeneration and repair in the murine mandible. Bone. 2012 May; 50(5):1184-7.
-
Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1 alpha and induction of autophagy in SH-SY5Y cells. Neurochem Int. 2010 Oct; 57(3):198-205.
-
HIF-1alpha dysfunction in diabetes. Cell Cycle. 2010 Jan 01; 9(1):75-9.
-
The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci U S A. 2009 Aug 11; 106(32):13505-10.